Background
Methods
Literature search strategy
Review of the abstracts and full-text articles
Quality indicators
Results
Study characteristics
Study design, n (%) | |
---|---|
Comparator: RCT | 3 (5) |
Comparator: cohort | 14 (22) |
Cohort | 45 (69) |
Comparator: case control | 3 (5) |
Study type, n (%) | |
Longitudinal | 12 (18) |
Cross-sectional | 53 (82) |
Study setting, n (%) | |
In person | 18 (28) |
Remote | 42 (65) |
NS | 5 (8) |
Decade of publication | |
Before 1995 | 6 (9) |
1995 to 2004 | 25 (38) |
2005 to June 2015 | 34 (52) |
Study sponsor, n (%) | |
Cooperative group | 7 (11) |
Investigator initiated | 58 (89) |
Geographic location, n (%) | |
USA | 19 (29) |
Norway | 17 (26) |
Netherlands | 7 (11) |
Germany | 4 (6) |
Other Europe | 10 (15) |
South America | 4 (6) |
Canada | 3 (5) |
Asia | 1 (2) |
n (HL patients) | |
Median (range) | 132 (12–3208) |
25–75th percentile | 58–280 |
Treatment status, n (%) | |
Active and off treatment | 6 (9) |
Off treatment only | 59 (91) |
Agea
| |
Mean (n = 33) | 39.6 |
Median (n = 21) | 38 |
Gender, % | |
Female (n = 54) | 44.0 % |
Range | 0–100 % |
Primary Author | Year | Design | Study Type | Timepoints (as reported) | N (HL Specific) | Age (HL specific) | Tx Status | Measures | Domains Assessed | Quality Score |
---|---|---|---|---|---|---|---|---|---|---|
Fobair P [26] | 1986 | Cohort | Cross-sectional | Median 9 years post treatment | 403 | 36.3 mean | Off | CES-D, Study-specific questionnaire | Domain, Symptom | 6 |
Kornblith AB [22] | 1990 | Cohort | Cross-sectional | 6.3 years mean post treatment | 273 | 37 mean | Off | PAIS-SR, BSI, POMS, IES, Global Sexual Satisfaction Index | Domain | 5 |
Chao NJ [37] | 1992 | Cohort | Longitudinal | <1 year post treatment | 24 | N/S | Off | Study-specific questionnaire | MultiD | 2 |
Kornblith AB [23] | 1992 | Cohort | Cross-sectional | Mean 6.3 years post treatment | 273 | 37 mean | Off | PAIS-SR, BSI, POMS, Global Sexual Satisfaction Index | Domain | 6 |
Kornblith [48] AB | 1992 | Cohort | Cross-sectional | Mean 2.2 years post treatment | 93 | 35 median | Off | PAIS-SR, BSI, POMS, IES | Domain | 4 |
Bloom JR [49] | 1993 | Comparator: Cohort | Cross-sectional | 1 or more years post treatment | 85 | 32.3 mean | Off | POMS, CES-D, Social Activity Scale | Domain | 6 |
van Tulder MW [30] | 1994 | Comparator: Cohort | Cross-sectional | Mean 14 years since diagnosis | 81 | 43.6 mean | Off | SF-36, Maudsley Martital Questionnaire | MultiD, Other | 6 |
Joly F [38] | 1996 | Comparator: Case Control | Cross-sectional | Mean 10 years since diagnosis | 93 | 42 mean | Off | EORTC QLQ-C30, Study-specific questionnaire | MultiD, Other | 6 |
Norum J [50] | 1996 | Cohort | Cross-sectional | Median 48 months since diagnosis | 42 | 38 median | Off | IES, VAS | Domain, Other | 4 |
Norum J [51] | 1996 | Cohort | Cross-sectional | Median 48 months since diagnosis | 42 | 38 median | Off | EuroQol | MultiD | 4 |
Norum J [52] | 1996 | Cohort | Cross-sectional | Median 48 months since diagnosis | 42 | 38 median | Off | EORTC QLQ-C30 | MultiD | 3 |
Abrahamsen AF [29] | 1998 | Cohort | Cross-sectional | Mean 12 years since diagnosis | 459 | 44 median | Off | Study-specific questionnaire | Domain | 6 |
Kornblith AB [24] | 1998 | Comparator: Cohort | Cross-sectional | Mean 5.9 years post treatment | 273 | 37 median | Off | PAIS-SR, BSI, POMS, IES | Domain | 6 |
Greil R [13] | 1999 | Cohort | Cross-sectional | Mean 10.5 years since diagnosis | 126 | 36.9 mean | Off | EORTC QLQ-C30 | MultiD | 6 |
Kaasa S [53] | 1999 | Comparator: Cohort | Cross-sectional | 3–20 years post treatment | 459 | 44 mean | Off | SF-36, FQ | MultiD, Symptoms | 5 |
Loge JH [54] | 1999 | Cohort | Cross-sectional | Mean 12.2 years since diagnosis | 459 | 44 mean | Off | HADS, FQ | Domain, Symptom | 6 |
Loge JH [55] | 1999 | Cohort | Cross-sectional | Mean 12.2 years since diagnosis | 459 | 44 mean | Off | SF-36 | MultiD | 6 |
Van Schaik CS [56] | 1999 | Cohort | Cross-sectional | Median 21.9 years since diagnosis | 33 | 21.9 median | Off | HUI2, HUI3 | MultiD | 3 |
Loge JH [32] | 2000 | Cohort | Cross-sectional | 3–23 years post treatment | 421 | 19–74 years | Off | FQ, HADS, Study-specific questionnaire | Domain. Symptom | 6 |
Barr RD [57] | 2001 | Comparator: Cohort | Cross-sectional | Completed treatment at least 2 years prior | 19 | N/S | Off | HUI | MultiD | 2 |
Cameron CL [58] | 2001 | Cohort | Cross-sectional | Median 7 years since diagnosis | 272 | 37 mean | Off | PAIS-SR, Symptom Report | Domain, Symptom | 4 |
Knobel H [35] | 2001 | Cohort | Cross-sectional | Mean 9 years since diagnosis | 92 | 37 mean | Off | FQ | Symptom | 6 |
Zabora J [59] | 2001 | Cohort | Cross-sectional | 58 % diagnosed within 90 days from study | 135 | N/S | Both | BSI | Domain | 3 |
Zebrack BJ [43] | 2002 | Comparator: Cohort | Cross-sectional | Mean 16.2 years since diagnosis | 1843 | 30.8 mean | Off | BSI | Domain | 5 |
Ganz PA [10] | 2003 | Comparator: RCT | Longitudinal | Trial registration (since diagnosis) | 244 | 31.4 STLI, 33.7 CMT median | Both | SF-36, CARES-SF, SDS | MultiD, Symptom | 4 |
Gil-Fernández JJ [27] | 2003 | Cohort | Cross-sectional | Median 7.6 years since diagnosis | 46 | 43 mean | Off | EORTC QLQ-C30, HADS | MultiD, Other | 5 |
Oldervoll LM [36] | 2003 | Cohort | Longitudinal | Mean post treatment: 6.6 years fatigued patients; 4.9 years non-fatigued patients | 53 | 41 fatigue, 40 non-fatigued mean | Off | SF-36, FQ | MultiD, Symptom | 5 |
Rüffer JU [33] | 2003 | Comparator: Case Control | Cross-sectional | Median 5.2 years since diagnosis | 818 | 31 median | Off | EORTC QLQ-C30, MFI, Life Situation Questionnaire | MultiD, Symptom | 5 |
Wettergren L [60] | 2003 | Cohort | Cross-sectional | Mean 14 years since diagnosis | 121 | 47 mean | Off | SEIQol-DW | MultiD | 5 |
Adams MJ [16] | 2004 | Cohort | Cross-sectional | Median 14.3 years since diagnosis | 48 | 31.9 median | Off | SF-36, Study-specific questionnaire | MultiD | 4 |
Wettergren L [28] | 2004 | Cohort | Cross-sectional | Mean 13 years since diagnosis | 121 | 47 median | Off | SF-12, SEIQoL-DW, HADS | MultiD, Domain | 6 |
Hjermstad MJ [61] | 2005 | Cohort | Cross-sectional | Median 16.3 years since diagnosis | 496 | 46 median | Off | FQ | Symptom | 6 |
Ng AK [34] | 2005 | Comparator: Cohort | Cross-sectional | Median 15 years since diagnosis | 511 | 44 median | Off | FACIT-Fatigue | Symptom | 6 |
Wettergren L [62] | 2005 | Cohort | Cross-sectional | Median 14 years since diagnosis | 121 | NS | Off | SF-12, SEIQoL-DW | MultiD | 2 |
Hjermstad MJ [63] | 2006 | Cohort | Cross-sectional | Median 16.3 years since diagnosis | 479 | 46 mean | Off | SF-36, FQ | MultiD, Symptom | 5 |
Mols F [21] | 2006 | Cohort | Cross-sectional | 5–15 years since diagnosis | 132 | NS | Off | SF-36, QoL-CS | MultiD | 6 |
Absolom K [64] | 2007 | Cohort | Cross-sectional | 15.7 years mean since diagnosis | 50 | 39.7 mean | Off | SF-12, HADS | MultiD, Domain | 5 |
Aksnes LH [65] | 2007 | Comparator: Cohort | Cross-sectional | Mean since diagnosis: 14 years for males, 11 years for females | 89 | 35 mean | Off | SF-36, HADS, FQ | MultiD, Domain, Symptom | 4 |
Oldervoll LM [66] | 2007 | Cohort | Cross-sectional | Mean 17 years since diagnosis | 476 | 46 mean | Off | FQ | Symptom | 5 |
Goodman KA [19] | 2008 | Cohort | Cross-sectional | Median 12 years post treatment | 60 | 43 median | Off | EORTC QLQ-C30 | MultiD | 6 |
Mulrooney DA [67] | 2008 | Comparator: Cohort | Cross-sectional | At least 15 years since diagnosis | 995 | NS | Off | FACIT-Fatigue, Pittsburgh Slee Quality Index, Epworth Sleepiness Scale | Symptoms | 4 |
Shimoda S [68] | 2008 | Cohort | Cross-sectional | Mean 16.5 years since diagnosis | 15 | NS | Off | HUI3 | MultiD | 2 |
Kiserud CE [14] | 2009 | Cohort | Cross-sectional | Mean 15.2 follow up years | 138 | 45.7 mean | Off | BSFI, Fatigue questionnaire, HADS, SF-36 | MultiD, Symptom, Domain | 6 |
Heutte N [11] | 2009 | Comparator: RCT | Longitudinal | Mean 7.5 years since diagnosis | 935 | 31 median | Off | EORTC QLQ-C30, MFI, Sexual Function Scale | MultiD, Symptoms | 6 |
Brandt J [69] | 2010 | Cohort | Cross-sectional | Median since diagnosis: HDCT 11 years, conventional chemotherapy 3.5 years | 98 | 46 HDCT, 41 conventional median | Off | EORTC QLQ-C30, EQ-5D | MultiD | 6 |
Klaassen RJ [40] | 2010 | Cohort | Longitudinal | 2 weeks after first course of chemotherapy | 49 | 14.7 mean | Both | PedsQL, HUI2, HUI3, EuroQol, Lanksy Play-Performance Score | MultiD, Other | 4 |
Klaassen RJ [41] | 2010 | Comparator: Cohort | Longitudinal | 2 weeks after first course of chemotherapy | 49 | 14.7 mean | Both | PedsQL, HUI2, HUI3, EuroQol, Lanksy Play-Performance Score | MultiD, Other | 2 |
Miltényi Z [17] | 2010 | Cohort | Cross-sectional | Mean 9.8 years since diagnosis | 168 | 43.11 median | Off | EORTC QLQ-C30 | MultiD | 6 |
Baptista RLR [70] | 2012 | Cohort | Cross-sectional | Median 7 years since diagnosis | 200 | 29 median | Off | MFI | Symptom | 4 |
Khimani N [18] | 2013 | Cohort | Longitudinal | Median 24 years since diagnosis | 273 | 52 median | Off | SF-36, FACIT-Fatigue | MultiD, Symptom | 5 |
Minn AY [20] | 2012 | Cohort | Cross-sectional | Median 10.2 years post treatment | 71 | 26 median | Off | EORTC QLQ-C30 | MultiD | 5 |
Behringer K [12] | 2013 | Comparator: RCT | Longitudinal | At diagnosis | 3208 | 36.4 mean | Both | EORTC QLQ-C30, MFI, Sexual Health Scale | MultiD, Symptoms | 6 |
Greaves P [39] | 2014 | Comparator: Cohort | Cross-sectional | Mean 20.3 years since diagnosis | 280 | 53.1 mean | Off | FACT-BMT, IOC, Study-specific questionnaire | MultiD, Other | 5 |
Hamre H [44] | 2013 | Comparator: Cohort | Cross-sectional | Median 21.5 years since diagnosis | 68 | 35 median | Off | FQ | Symptom | 5 |
Kim S [71] | 2014 | Cohort | Cross-sectional | Mean 6.7 years since diagnosis | 58 | 43.3 mean | Off | EORTC QLQ-C30, HADS | MultiD, Domain | 6 |
Roper K [72] | 2013 | Cohort | Longitudinal | At completion of planned therapy | 40 | 30.9 mean | Off | SF-12, HADS, SDS, IOC | MultiD, Domain, Other | 4 |
Soares A [45] | 2013 | Cohort | Cross-sectional | Median 7 years since diagnosis | 200 | 29 median | Off | SF-12, QOL-CS, MOS-SSS, MFI | MultiD, Symptom | 4 |
Vissers PAJ [15] | 2013 | Cohort | Cross-sectional | Mean 5 years since diagnosis | 150 | 47 mean | Off | EORTC QLQ-C30 | MultiD | 6 |
Calaminus G [46] | 2014 | Cohort | Cross-sectional | Mean 15.3 years since diagnosis | 725 | 28.44 mean | Off | EORTC QLQ-C30 | MultiD | 6 |
Daniels LA [31] | 2014 | Cohort | Cross-sectional | Mean 4.6 years since diagnosis | 180 | 46 mean | Off | EORTC QLQ-C30, Fatigue Assessment Scale, Study-specific questionnaire | MultiD, Symtom, Domain | 6 |
Daniels LA [73] | 2014 | Cohort | Longitudinal | Mean 21 years since diagnosis | 43 | 47 mean | Off | EORTC QLQ-C30, Fatigue Assessment Scale, HADS | MultiD, Domain, Symptom | 4 |
Oerlemans S [25] | 2014 | Comparator: Case Control | Longitudinal | Mean 4.7 years since diagnosis | 180 | 46.1 mean | Off | EORTC QLQ-C30, HADS | MultiD, Domain | 6 |
Vermaete N [47] | 2014 | Comparator: Cohort | Longitudinal | Before the start of chemotherapy | 12 | 47 mean | Both | EORTC QLQ-C30, Distress Barometer | MultiD, Domain | 5 |
Kiserud CE [74] | 2015 | Cohort | Cross-sectional | Median 16 years since diagnosis | 131 | 46 median | Off | Fatigue questionnaire, HADS, SF36, | Symptom, MultiD | 5 |
Husson O [42] | 2015 | Comparator: Cohort | Cross-sectional | Mean 5.3 years since diagnosis | 150 | 46.6 mean | Off | Fatigue assessment scale | Symptom | 4 |
Patient characteristics
Quality of life measures
HRQL measures, n (%)a
| Longitudinal | Cross-sectional |
---|---|---|
n = 12 (18) |
n = 53 (82) | |
Multidimensional | 12 (100) | 33 (62) |
Domain | ||
Psychosocial | 4 (33) | 20 (38) |
Sexual functioning | 2 (17) | 5 (9) |
Physical | 1 (8) | 0 (0) |
Symptom | ||
Fatigue | 4 (33) | 18 (34) |
Pain | 0 (0) | 1 (2) |
Other | 2 (4) | 4 (8) |
Quality assessment
Quality indicator | Longitudinal (n = 12) | Cross-sectional (n = 53) | Total (N = 65) |
---|---|---|---|
Sample >50 (HL Specific) | 6 (42) | 45 (85) | 51 (78) |
Description of >=2 Demos (HL Specific) | 10 (83) | 48 (91) | 58 (89) |
Description of >=2 Clinical Variables (HL Specific) | 11 (92) | 45 (85) | 56 (86) |
HL Specific HRQL Scores (from validated measure) | 8 (67) | 45 (85) | 53 (82) |
Analysis of HL HRQL Scores × HL Characteristics | 8 (67) | 37 (70) | 45 (69) |
HL Results are compared between groups? | 9 (75) | 44 (83) | 53 (82) |